JNJ targets obesity

FRAMINGHAM (01/15/2004) - Johnson & Johnson Pharmaceutical Research Development is widening its collaboration with Entelos to include target validation, lead optimization, and clinical development in the area of obesity. Their investigations will involve use of Entelos' Metabolism PhysioLab, a mathematical model of human pathophysiology for simulating experiments and trials.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about Entelos

Show Comments